Pacer Advisors Inc. Has $7.50 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Pacer Advisors Inc. cut its position in Hologic, Inc. (NASDAQ:HOLX) by 64.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 92,113 shares of the medical equipment provider’s stock after selling 166,682 shares during the quarter. Pacer Advisors Inc.’s holdings in Hologic were worth $7,504,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Innealta Capital LLC bought a new position in Hologic in the second quarter valued at about $25,000. Wolff Wiese Magana LLC acquired a new position in Hologic during the 3rd quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new position in Hologic during the 1st quarter worth approximately $37,000. Sunbelt Securities Inc. acquired a new stake in Hologic in the second quarter valued at approximately $37,000. Finally, First Horizon Advisors Inc. boosted its position in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and dropped their price target for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Tuesday, October 15th. Royal Bank of Canada upped their price objective on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Evercore ISI upped their price target on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Trading Up 0.3 %

HOLX opened at $78.97 on Friday. The stock has a market cap of $18.34 billion, a PE ratio of 23.71, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67. The company has a fifty day moving average of $80.44 and a 200-day moving average of $78.34.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the company posted $0.89 EPS. On average, sell-side analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.